Targeting Mitochondrial Dysfunction

For our lead product, Imeglimin, a New Drug Application was submitted in Japan by Sumitomo Dainippon Pharma in July 2020. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Announces Completion of Arbitration with Merck Serono

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Announces Completion of Arbitration with Merck Serono

Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update

As of December 31, 2020, cash and cash equivalents were EUR 40.2 million (USD 49.4 million) New results from the PXL770 Phase 2a STAMP-NAFLD trial for the treatment of NASH showed consistently greater response in…

Read this Press Release: Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update

Poxel Regains Imeglimin Rights From Metavant

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Regains Imeglimin Rights From Metavant
Click here to show the previous slide Click here to show the next slide

Upcoming Events

H.C. Wainwright Global Life Science Conference

2021 NASH Tag conference

Mitochondria-Targeted Drug Development Summit

Kempen Life Sciences Conference

Japan Diabetes Society

Jefferies Global Healthcare Conference

Click here to show the previous slide Click here to show the next slide